Insider Transactions in Q3 2023 at Evelo Biosciences, Inc. (EVLO)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
1,996
-10.64%
|
$5,988
$3.94 P/Share
|
|
Sep 27
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+44.44%
|
-
|
|
Aug 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,004
-18.1%
|
$18,036
$9.51 P/Share
|
|
Aug 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,434
-30.19%
|
$30,906
$9.51 P/Share
|
|
Aug 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
342
-8.35%
|
$3,078
$9.51 P/Share
|
|
Aug 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
3,128
-15.84%
|
$28,152
$9.51 P/Share
|
|
Aug 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+36.99%
|
-
|
|
Aug 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+36.36%
|
-
|
|
Aug 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,171
+22.23%
|
-
|
|
Aug 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
6,625
+25.12%
|
-
|
|
Jul 11
2023
|
Flagship Ventures Fund Iv General Partner LLC |
BUY
Open market or private purchase
|
Indirect |
5,411,255
+43.26%
|
$10,822,510
$2.31 P/Share
|